NPPB and hydrops fetalis: Empagliflozin reduced the risk of the composite of CV death or HF hospitalization by 21% (HR 0.79), with a consistent benefit in both non-diabetic and diabetic subgroups. Furthermore, Santos-Gallego et al. conducted an RCT that was exclusively for non-diabetic HFrEF patients, which demonstrated improvements in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, exercise capacity, and LV remodeling [24].